Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31574295 | 1.00 | MAPK14 (0.46) | MAPK14KDM4CROCK2S1PR1S1PR3 | |
| SCHEMBL21957297 | 0.69 | AR (0.50) | ARNR3C1 | |
| SCHEMBL21807325 | 0.68 | MCHR1 (0.43) | CYP3A4 | |
| SCHEMBL17940518 | 0.67 | ROCK2 (0.53) | ROCK2 | |
| SCHEMBL21807233 | 0.66 | ADORA3 (0.42) | KDM4CROCK2 | |
| SCHEMBL16592460 | 0.66 | ROCK2 (0.46) | KDM4CROCK2CYP1A2 | |
| SCHEMBL29355852 | 0.66 | ROCK2 (0.46) | KDM4CROCK2CYP1A2 | |
| SCHEMBL21807514 | 0.66 | KDM4E (0.53) | ROCK2CYP1A2CYP3A4 | |
| SCHEMBL31331911 | 0.64 | AR (0.43) | ARNR3C1BRD4 | |
| SCHEMBL23357558 | 0.64 | BCL6 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4414365-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-01-27 | — | — | US | disclosed |
| EP-3941475-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113939295-A | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2022-01-14 | — | — | CN | disclosed |
| EP-3852533-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11046690-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| CN-112911935-A | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2021-06-04 | — | — | CN | disclosed |
| WO-2020191056-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191056-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-09-10 | — | — | US | disclosed |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-09-10 | — | — | US | disclosed |
| US-10654850-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654850-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200102301-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-04-02 | — | — | US | disclosed |
| WO-2020061162-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | MAPK14 2251/4885KDM4C 2106/4885ROCK2 3190/4885 |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | MAPK14 1712/4885KDM4C 3104/4885ROCK2 2943/4885 |
| US-20200102301-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | MAPK14 2251/4885KDM4C 2106/4885ROCK2 3190/4885 |
| US-11046690-B2 | Pyridazinones and methods of use thereof | ATP6V1B1, GLS, REN | MAPK14 2251/4885KDM4C 2106/4885ROCK2 3190/4885 |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | MAPK14 2251/4885KDM4C 2106/4885ROCK2 3190/4885 |
| US-10654850-B2 | Pyridazinones and methods of use thereof | ATP6V1B1, GLS, REN | MAPK14 2251/4885KDM4C 2106/4885ROCK2 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.